Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 42.86 percent increase over losses of
Express News | Design Therapeutics Inc - Qtrly Shr Loss $0.20
Design Therapeutics | 10-Q: Quarterly report
Express News | Design Therapeutics Q1 Operating Income USD -14.4 Million
Express News | Design Therapeutics Q1 Net Income USD -11.105 Million
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients
PEGY, MTC and IMTE Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Biov
Express News | Design Therapeutics Shares Are Trading Higher After Piper Sandler Upgraded the Stock From Neutral to Overweight and Raised Its Price Target From $6 to $12
Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral
Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral.
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will
Buy Rating Justified by Design Therapeutics' Innovative Pipeline and Solid Financials
Design Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 203.8% Piper Sandler $6 → $12 Upgrades Neutral → Overweight 03/20/2024 1.27% RBC Capital → $4 R
Express News | Design Therapeutics Inc : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $12 From $6
Independent Director of Design Therapeutics Picks Up 88% More Stock
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Design Therapeutics(DSGN.US) Director Buys US$99,738.48 in Common Stocks
$Design Therapeutics(DSGN.US)$ Director Schmid John P. purchased 26,965 shares of Common Stocks on Mar 22, 25, 2024 at an average price of $3.6988 for a total value of $99,738.48.Source: Announcement
No Data